The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F21%3A00074821" target="_blank" >RIV/65269705:_____/21:00074821 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14110/21:00122607
Výsledek na webu
<a href="https://iv.iiarjournals.org/content/35/6/3345" target="_blank" >https://iv.iiarjournals.org/content/35/6/3345</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/invivo.12632" target="_blank" >10.21873/invivo.12632</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms
Popis výsledku v původním jazyce
Background/Aim: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). Patients and Methods: In a cohort of 206 patients with MPN, MPs' procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while plateletand erythrocyte-MPs were enumerated by flow cytometry in 558 samples. Results: MPN patients had higher MP levels than the control group. The levels of MPs were higher in male patients, smokers, and those who were older than 60 years, and in the presence of JAK2(V)(617F) mutation, history of thrombosis, platelets >400 x 10(9)/l, hematocrit >45%, or leukocytes >10x 10(9)/l. Cytoreductive treatment reduced MP levels, with anagrelide being associated with lower MP levels than hydroxyurea. Conclusion: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.
Název v anglickém jazyce
The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms
Popis výsledku anglicky
Background/Aim: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). Patients and Methods: In a cohort of 206 patients with MPN, MPs' procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while plateletand erythrocyte-MPs were enumerated by flow cytometry in 558 samples. Results: MPN patients had higher MP levels than the control group. The levels of MPs were higher in male patients, smokers, and those who were older than 60 years, and in the presence of JAK2(V)(617F) mutation, history of thrombosis, platelets >400 x 10(9)/l, hematocrit >45%, or leukocytes >10x 10(9)/l. Cytoreductive treatment reduced MP levels, with anagrelide being associated with lower MP levels than hydroxyurea. Conclusion: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2021
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
In Vivo
ISSN
0258-851X
e-ISSN
—
Svazek periodika
35
Číslo periodika v rámci svazku
6
Stát vydavatele periodika
GR - Řecká republika
Počet stran výsledku
9
Strana od-do
3345-3353
Kód UT WoS článku
000711693300017
EID výsledku v databázi Scopus
2-s2.0-85119254439